Northwire Canada EditionTuesday, July 14, 2026
Sign inSubscribe
Northwire
⌕
WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8% WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8%
Regulatory

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI(TM) (tafasitamab) for Follicular Lymphoma in Argentina and Mexico

By The Northwire Desk — AI Analysis Mar 17, 2026 · 07:30 GUD · 6.14 KNIGHT THERAPEUTICS INC.
GUD · Price

Executive Summary

  • Knight Therapeutics’ Argentine and Mexican affiliates have filed supplemental applications with ANMAT and COFEPRIS to obtain approval for MINJUVI® (tafasitamab) in combination with lenalidomide and rituximab for relapsed/refractory follicular lymphoma (FL).
  • The submissions follow successful launches of MINJUVI® in Brazil, Mexico, and Argentina for diffuse large B‑cell lymphoma (DLBCL) and a recent approval for FL in Brazil.
  • Expansion of the MINJUVI® label into additional Latin American markets could significantly broaden Knight’s commercial footprint and revenue potential for this oncology portfolio.

Key Details

  • Regulatory filings:
  • Laboratorio LKM S.A. (Argentina) – supplemental application to ANMAT.

  • Grupo Biotoscana de Especialidad S.A. de C.V. (Mexico) – supplemental application to COFEPRIS.

  • Indication sought: MINJUVI® + lenalidomide + rituximab for adult patients with relapsed or refractory follicular lymphoma (Grade 1‑3a) after ≥ one prior systemic therapy line.

  • Current market presence:

  • Exclusive Latin America supply/distribution agreement with Incyte (Sept 2021).

  • MINJUVI® launched in Brazil, Mexico, Argentina for DLBCL; approved in Brazil for FL (Mar 2026).

  • Clinical background:

  • Phase 3 inMIND study demonstrated median PFS of 22.37 months vs 13.93 months (HR 0.434, p < 0.0001) for tafasitamab + R2 versus placebo + R2 in relapsed/refractory FL/MZL.

  • Strategic significance:

  • Adds a new indication to the product’s label across two major Latin American markets.

  • Enhances Knight’s portfolio depth, potentially increasing sales volume and market share in oncology.

  • CEO comment (Samira Sakhia): Emphasized progress of MINJUVI® launches, recent FL approval in Brazil, and the importance of expanding indications to meet diverse patient needs.

Notable Quotes

“We continue to advance our pipeline with the submissions for MINJUVI® in both Argentina and Mexico… MINJUVI® is more than a single product. With approvals across distinct indications, it effectively represents multiple therapies within one brand…” – Samira Sakhia, President & CEO, Knight Therapeutics

Materiality Assessment: Material – Positive (potential to generate additional revenue streams and broaden market coverage).

Read the original news release →

More from KNIGHT THERAPEUTICS INC.

Jun 17, 2026 · 17:30

Debt-free balance sheet achieved ahead of schedule, but the credit win was already telegraphed by Q1 cash flow and priced into the +11% run-up.

Other Jun 05, 2026 · 18:00

Knight Announces Early Warning Filing Regarding Shares of Crescita

M&A / Property May 27, 2026 · 18:00

LATAM Expansion Validates Growth Strategy But FX and Generic Risks Loom

Other May 08, 2026 · 06:30

Knight Therapeutics scores Brazilian approval for TAVALISSE just as record sales lift stock to all‑time high

Regulatory May 07, 2026 · 06:30

Knight Therapeutics Q1 Earnings Beat Drives Guidance Hike Amidst LATAM Expansion

Earnings Mar 19, 2026 · 07:30

Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results

Earnings